Publications

Latest publication 01/01/2006

Trehalose reduces aggregate formation and delays pathology in a transgenic mouse

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disease that presents in the fifth or sixth decade with dysphagia, ptosis and...

Array
(
    [id_prestablog_news] => 72
    [id_shop] => 1
    [date] => 2006-01-01 00:00:00
    [date_modification] => 2024-02-09 14:15:11
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [prim_key] => 143
    [id_lang] => 1
    [title] => Trehalose reduces aggregate formation and delays pathology in a transgenic mouse
    [paragraph] => Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
    [content] => 
Authors
J. E. Davies, S. Sarkar, D. C. Rubinsztein.

 Lab
Addenbrooke's Hospital, Cambridge Institute for Medical Research, Department of Medical Genetics, Cambridge, UK.
Journal
Human Molecular Genetics
Abstract
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disease that presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness. OPMD is caused by the abnormal expansion of a polyalanine tract within the coding region of poly(A) binding protein nuclear 1 (PABPN1). The resultant mutant PABPN1 forms aggregates within the nuclei of skeletal muscle fibres. We have previously described a transgenic mouse model of OPMD that recapitulates the human disease and develops progressive muscle weakness accompanied by the formation of aggregates in skeletal muscle nuclei. The chemical chaperone trehalose has been used effectively to alleviate symptoms in a mouse model of Huntington's disease and is thought to elicit its effect by binding and stabilizing partially folded polyglutamine proteins and inhibiting the formation of aggregates. Here, we show that trehalose reduces aggregate formation and toxicity of mutant PABPN1 in cell models. Furthermore, oral administration of trehalose attenuated muscle weakness, reduced aggregate formation and decreased the number of TUNEL-labelled nuclei in skeletal muscle in an OPMD transgenic mouse model. Thus, anti-aggregation therapy may prove effective in the treatment of human OPMD.
BIOSEB Instruments Used
Grip strength test (BIO-GS3)
    [meta_description] => 
    [meta_keywords] => http://hmg.oxfordjournals.org/content/15/1/23.short#corresp-1
    [meta_title] => 
    [link_rewrite] => trehalose-reduces-aggregate-formation-and-delays-pathology-in-a-transgenic-mouse-model-of-oculopharyngeal-muscular-dystrophy-
    [actif_langue] => 1
    [read] => 977
    [count_comments] => 0
    [id] => 72
    [categories] => Array
        (
            [26] => Array
                (
                    [id_prestablog_categorie] => 26
                    [title] => Miscellaneous research domains
                    [link_rewrite] => Miscellaneous-research-domains
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of [...]
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [48] => Array
                (
                    [name] => Grip strength test
                    [description_short] => 
An easy way to objectively quantify the muscular strength of mice and rats, and to assess the effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration. It is widely used in conjunction with the ROTAROD motor coordination test: a normally coordinated rodent will show a decreased latency to fall off the rotating rod if its muscular strength is low. The Grip Strength Test is a must for your research on activity, motor control & coordination, and is particularly well suited for studies on Parkinson's & Huntington's disease.
New features GS4 - 2023: Color display with permanent backlight screen for easier reading, reset by footswitch, Improved battery time, Larger data memory of 500 values, Animal counter, USB port (charging/data transfer)

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://bioseb.com/en/activity-motor-control-coordination/48-grip-strength-test.html
                )

        )

)
1